Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Fidia Spa ( (IT:FDA) ) is now available.
Fidia S.p.A. has issued its November 2025 monthly financial disclosure under CONSOB’s special transparency regime, providing updated information on the group’s net financial position, overdue debt by category, and changes in related-party relationships, while noting that the figures are prepared under IFRS and remain unaudited. The company also outlines the status and regulatory treatment of its structured financing arrangements, including a fully converted 2022–2024 convertible bond program and the ongoing 2025 convertible bond with warrants reserved to Global Growth Holding Limited, for which CONSOB now requires detailed, recurring disclosure on subscription, conversion activity, costs and the role of these instruments in supporting Fidia’s industrial and financial plans, underscoring the level of regulatory scrutiny and the importance of these financings to the company’s capital structure and continuity of operations.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.15 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
More about Fidia Spa
Fidia S.p.A. is an Italian company listed on Euronext Milan that prepares its financial statements under IFRS. The group operates in a regulated environment overseen by CONSOB and is subject to enhanced transparency requirements on its economic and financial situation, including regular disclosure of its net financial position, overdue debts, and related-party transactions.
Average Trading Volume: 889,345
Technical Sentiment Signal: Strong Sell
Current Market Cap: €2.96M
See more insights into FDA stock on TipRanks’ Stock Analysis page.